Health Innovation Technology Transfer, S.L.
  • Team
  • Clients
  • Services
    • Business Development
    • Market Access Strategy
    • Healthcare Planning
  • R&D
  • Fundació HiTT
  • News
  • Contact

Category: pharma

THE DEVELOPMENT OF COVID-19 THERAPIES: A MULTIDISCIPLINARY APPROACH TO A COMPLEX ISSUE

Posted on 07/07/202007/07/2020 by Maria Nieto

The immune system is amazingly complex, precise and synchronised to deliver effective responses against most health insults. Likewise, medical challenges need to be faced with a multidisciplinary, coordinated and target-specific approach.

Posted in covid19, epidemics, healthcare, hitt, pandemics, pharma, research

The use of indicators to monitor quality of care

Posted on 15/06/202015/06/2020 by Maria Nieto

In 2016, AQuAS (Catalan Agency for Health Quality and Evaluation), defined indicators used to evaluate the clinical and healthcare quality as a measurement instrument used to evaluate or measure specific aspects of the quality of care.

Posted in healthcare, hitt, market access, pharma, publichealth, research, technology
www.devex.com

QUALITY OVER QUANTITY, AN EXPERT-BASED EVALUATION

Posted on 27/05/202025/05/2020 by Maria Nieto

The R&D response to the SARS-CoV-2 outbreak has been massive, promoted by unprecedented funding to support innovative solutions to fight the COVID-19 pandemic.

Posted in healthcare, hitt, investment, pharma, research, technology Tagged healthcare, hitt, investment, research, technology

The Start-up Graveyard

Posted on 13/05/202013/05/2020 by Maria Nieto

Across all industries 9 out of 10 start-ups will fail. This staggering statistic doesn’t exactly inspire confidence. In healthcare the failure-rate may not be as detrimental but remains cause for concern. Which begs the question: why do so many start-ups fail?

Posted in healthcare, hitt, market access, pharma

New acquisition cost of Repatha

Posted on 25/10/2018 by Maria Nieto

Today we learn that Amgen is lowering the acquisition cost of Repatha by 60% in the US.

Posted in healthcare, pharma

Gene therapy: Will it deliver its commercial promise?

Posted on 18/04/201826/04/2018 by webmaster

On April 10th 2018, Goldman Sachs published “The Genome Revolution” report on gene therapy, in which its analyst posed the thought-provoking question: “is curing patients a sustainable business model?”

Posted in healthcare, pharma

Drugs in the graveyard increase costs

Posted on 22/03/201822/03/2018 by Oriol Solà-Morales

This week we learned that Merck & Co. was ending the Phase III APECS study of Verubecestat (formerly known as MK-8931) for the treatment of prodromal Alzheimer Disease. Yet another drug in AD graveyard!!

Posted in pharma

Biotech and pharmaceutical Postgraduate study

Posted on 02/11/2017 by webmaster

Dr. Solà-Morales has been selected to become one of the professors that will teach in this postgraduate study provided by the IQS (Instituto Químico de Sarrià).

Posted in education, pharma, training

Posts navigation

← Older posts
Legal Notices
Cookies Policy
Privacy Policy

Health Innovation Technology Transfer, S.L.

This website uses cookies to improve your experience. We'll assume you accept this policy as long as you are using this websiteAcceptView Policy
This page uses cookies and other technologies so that we can improve your experience on our sites: More information about our cookies policy.